Adcytherix Raises €30M in Seed Funding to Develop Novel ADCs

Adcytherix raises €30M in Seed Funding

Marseille-based biopharmaceutical company Adcytherix has secured €30M in seed funding to accelerate the development of novel antibody drug conjugates (ADC) for the treatment of diseases like cancer. This funding round, led by Pontifax, brings together a strong consortium of investors and positions Adcytherix for significant growth in the biopharmaceutical industry.

Funding Amount: €30 million

Industry: Biopharmaceuticals

Employee Count: 2-10

CEO: Seamus McAteer (CEO Linkedin)

What Adcytherix needs to buy: Adcytherix is actively seeking collaborations with biotech companies, research institutions, and manufacturers to advance the development, production, and distribution of their novel antibody drug conjugates (ADCs). Companies specializing in oncology, pharmaceutical research and development, and regulatory compliance services are ideal partners to support Adcytherix in their mission to revolutionize cancer treatment and improve patient outcomes.